Literature DB >> 1132367

[Dipropylacetamide in the treatment of manic-depressive psychosis].

P A Lambert, G Carraz, S Borselli, M Bouchardy.   

Abstract

Dipropylacetamide, which was first used as a treatment of epilepsy, turned out to be also a normalizing agent of the periodic avolution of manic-depressive psychosis. The therapeutic action of dipropylacetamide has several effects: 1) total suppression of the fits; 2) reduced intensity of these fits; 3) increasing lapse of time between two fits; 4) greatest response to anti-depressants and neuroleptics which can be prescribed in much smaller doses. More manic than depressive states respond to dipropylacetamide. The average doses are about 900 mg or so. Cautiousness if advisable at the beginning of the treatment on account of the use of sedatives; but the treatment is extremely well received and accepted by the patients during periods of several years without the requirement of biological controls. Associating lithium with dipropylacetamide often yields remarkable results.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1132367

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  6 in total

Review 1.  Pharmacodynamic effects and possible therapeutic uses of THIP, a specific GABA-agonist.

Authors:  A V Christensen; O Svendsen; P Krogsgaard-Larsen
Journal:  Pharm Weekbl Sci       Date:  1982-10-22

2.  Use and safety of antiepileptic drugs in psychiatric inpatients-data from the AMSP study.

Authors:  Katrin Druschky; Stefan Bleich; Renate Grohmann; Rolf R Engel; Alexandra Kleimann; Susanne Stübner; Waldemar Greil; Sermin Toto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-08-01       Impact factor: 5.270

3.  Discriminative stimulus properties of valproic acid in the pigeon.

Authors:  M Picker; S Wallace; S Hancock; A Poling
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders.

Authors:  H M Emrich; D von Zerssen; W Kissling; H J Möller; A Windorfer
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1980

5.  Decreased mTOR signaling pathway in human idiopathic autism and in rats exposed to valproic acid.

Authors:  Chiara Nicolini; Younghee Ahn; Bernadeta Michalski; Jong M Rho; Margaret Fahnestock
Journal:  Acta Neuropathol Commun       Date:  2015-01-20       Impact factor: 7.801

6.  Retinal alterations in a pre-clinical model of an autism spectrum disorder.

Authors:  Christina Joselevitch; Luiz Roberto G Britto; Silvana Chiavegatto; Elisa Maria Guimarães-Souza
Journal:  Mol Autism       Date:  2019-04-15       Impact factor: 7.509

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.